Alzheimer's Disease: Concerned About Your Memory or Cognitive Decline?

Alzheimer’s disease is one of the leading causes of age-related cognitive decline and the most common cause of dementia.

Millions of Americans and tens of millions of people worldwide are affected by Alzheimer’s disease. Chances are, you know someone whose life has been impacted by this progressive neurological condition.

Despite its prevalence, early detection and accurate diagnosis remain challenging. Diagnostic tools and treatment options have historically been limited, making it difficult to identify the disease in its earliest stages and determine who may benefit from available therapies.

Early detection and accurate diagnosis are essential to making informed decisions about treatment, planning for the future, and managing cognitive health.

A More Comprehensive Approach to Alzheimer’s Disease Assessment

Valley Integrative Health offers a comprehensive assessment approach designed to evaluate genetic risk, identify biomarkers associated with Alzheimer’s disease, and support the diagnostic evaluation of cognitive decline.

Our approach combines established diagnostic methods with advances in genetic testing and blood-based biomarkers to provide a more complete picture of an individual’s risk and potential disease status.

Depending on the individual, assessment may include genetic risk testing, specialized laboratory testing, cognitive evaluation, and review of relevant neurological imaging and other diagnostic findings.

Understanding Your Genetic Risk: APOE ε4

One of the most significant genetic risk factors for late-onset Alzheimer’s disease is a variant of the apolipoprotein E gene known as APOE ε4 .

Research in the early 1990s established an association between APOE ε4 and an increased risk of developing Alzheimer’s disease. Subsequent studies have further clarified its role in disease susceptibility.

• One copy of APOE ε4: Associated with an increased risk of developing Alzheimer’s disease.
• Two copies of APOE ε4: Associated with a substantially higher risk than having one copy.

Depending on the population studied and other individual risk factors, people with one copy may have approximately two to three times the risk, while those with two copies may have an approximately eight- to twelve-fold risk compared with people who carry no copies.

However, genetic risk is not the same as a diagnosis. Having one or two copies of APOE ε4 does not mean that a person will inevitably develop Alzheimer’s disease, and people without this variant can still develop the condition.

Genetic testing can help clarify risk, but results must be interpreted in the context of personal and family history, other risk factors, and clinical findings.

Advances in Blood Testing for Alzheimer’s Disease

One of the most promising developments in Alzheimer’s disease assessment is the emergence of blood-based biomarkers.

Historically, evaluating the amyloid plaques and abnormal tau proteins associated with Alzheimer’s disease often required specialized brain imaging, such as positron emission tomography (PET), or analysis of cerebrospinal fluid obtained through a lumbar puncture.

Newer blood tests can measure specific forms of amyloid-beta and tau proteins associated with Alzheimer’s pathology. These tests offer a less invasive way to obtain information that may help clinicians evaluate individuals experiencing cognitive decline.

Amyloid-Beta Blood Testing

Amyloid-beta proteins are involved in the formation of amyloid plaques in the brains of people with Alzheimer’s disease.

A 2021 multi-cohort analysis published in Molecular Neurodegeneration evaluated blood-based amyloid-beta measurements and found that these biomarkers could help distinguish individuals with evidence of brain amyloid accumulation from those without it.

These findings helped advance the development of blood tests that may support the diagnostic evaluation of Alzheimer’s disease.

Phosphorylated Tau Blood Testing

Tau is another protein closely associated with Alzheimer’s disease. Certain abnormal forms, including phosphorylated tau, can provide valuable information about Alzheimer’s-related changes in the brain.

A 2024 study published in JAMA evaluated a blood test measuring phosphorylated tau and reported high diagnostic accuracy for identifying Alzheimer’s disease among individuals experiencing cognitive decline.

Additional research published in Alzheimer’s & Dementia in 2024 found that testing amyloid-beta and tau biomarkers together showed strong agreement with brain amyloid findings measured by PET imaging.

Together, these advances demonstrate the growing role of blood-based biomarkers in the assessment of Alzheimer’s disease.

What Can These Tests Tell You?

Depending on the specific tests used, blood-based biomarkers may help clinicians assess whether findings are consistent with Alzheimer’s-related amyloid pathology.

Some laboratory assessments provide results categorized as low, intermediate, or high likelihood of amyloid pathology . The interpretation depends on the particular test, its validated thresholds, and the clinical context.

These results may help determine whether additional evaluation is appropriate and whether confirmatory testing or specialist referral should be considered.

Importantly, not all blood tests have the same diagnostic performance, and a positive biomarker result does not automatically establish that Alzheimer’s disease is the cause of a person’s symptoms. Results must be interpreted alongside the patient’s symptoms, cognitive assessment, medical history, and other relevant findings.

The Valley Integrative Health Approach

At Valley Integrative Health, we combine genetic risk assessment and advanced blood-based biomarkers with established diagnostic methods, as appropriate for each patient.

Our comprehensive assessment may help:

• Evaluate genetic susceptibility to Alzheimer’s disease.
• Identify blood-based biomarkers associated with Alzheimer’s pathology.
• Support the evaluation of memory changes and cognitive decline.
• Determine whether additional neurological assessment or imaging may be appropriate.
• Establish a baseline for monitoring cognitive health and relevant biomarkers over time.

The goal is to provide a more informed understanding of individual risk and clinical findings, supporting appropriate next steps in care.

No single genetic test or blood test can identify every person who will develop Alzheimer’s disease or independently answer every diagnostic question. A comprehensive evaluation remains essential, and the appropriate assessment depends on each patient’s symptoms, history, and clinical needs.

Take a Proactive Approach to Your Cognitive Health

If you are concerned about memory changes, have a family history of Alzheimer’s disease, or want to better understand your risk, an individualized assessment may help clarify which evaluations are appropriate.

Valley Integrative Health offers early screening, comprehensive assessment, and evidence-informed care for individuals concerned about Alzheimer’s disease and cognitive health.

Selected Scientific and Educational References

• Mayo Clinic: Alzheimer’s genes
• National Institute on Aging: Research on APOE ε4 and dementia risk
• Molecular Neurodegeneration: Research on blood-based amyloid biomarkers
• JAMA: 2024 study of blood-based Alzheimer’s biomarkers
• Alzheimer’s biomarker research, 2024
• Quest Diagnostics: AD-Detect Aβ42/40 and p-tau217 Evaluation, Plasma